Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Theratechnologies Inc T.TH

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  THERF

Theratechnologies Inc is a pharmaceutical company addressing unmet medical needs in metabolic disorders. EGRIFTA is its registered trademark in the USA and it is used to commercialize its first product using its internally developed compound, tesamorelin.
Price: $1.72 | Change: $-0.08 | %Change: -4.44%
Volume: 349,520 | Day High/Low: 1.85/1.71 | 52 Week High/Low: 1.81/0.325
View modes: 
0 stars

RE:US potential

Don't forget that Egriffta is the sole approved treatment for that indication. So, in theory, it could achieve 100% market penetration.  rate and reply
0 stars

US potential

I think the major unknown for Thera is the realistic maximum number of patients on the drug that can be achieved. We still don't know if Serono was doing a poor job with this drug. Beyond the peak...read more
0 stars

RE:RE:RE:RE:Tesamorelin to be Assessed in the Treatment of Liver Disease

The market probably should assign some tiny probability of success at this point but also probably won't. At least not until closer to when the first test results are imminent. Since the company is...read more
0 stars

RE:RE:RE:Tesamorelin to be Assessed in the Treatment of Liver Disease

Even if the market attributed a 15-20% chance of working, and it did receive funding from the NIH, that chance alone could add significantly to the share price given the revenue potential.  rate and reply
0 stars

RE:RE:Tesamorelin to be Assessed in the Treatment of Liver Disease

In my estimation, there will not be any appreciation for this trial until the first results are published and that is probably more than a year away. Grinspoon must feel there is some reason to...read more
0 stars

RE:RE:RE:RE:RE:RE:RE:RE:3Q and 4Q Expectations

And happy belated Canada Day to you!  rate and reply
0 stars

RE:RE:RE:RE:RE:RE:RE:3Q and 4Q Expectations

Very good post SPCE01 BTW my Nick name is PALINC not PALIN Indeed I do not live in Wasilla and I cannot see Russia from my house !!LOL Happy 4 th of July long weekend  rate and reply
0 stars

RE:RE:RE:RE:RE:RE:3Q and 4Q Expectations

A few copmments: 1.) Sales were reported by Bloomberg today and the 4 week average hit a new high. I would love to share specifics but I think that is fas far as I should go.  2.) Don't know how...read more
0 stars

RE:Tesamorelin to be Assessed in the Treatment of Liver Disease

We didn't get a lift in the share price when it was announced but the new trial paid for by the NIH would be transformative in a very substantial way if successful given the rate of non-fatty liver...read more
0 stars

Institutions quietly buying this stock

If you look at the trades, insitutions are picking up all the shares at $1.80.  No news and the stock is slowly going up.  Love it.  rate and reply
0 stars

RE:RE:RE:RE:RE:3Q and 4Q Expectations

It think if Mr. Murphy stays away then the $10/share would be reachable.  We have seen some insider buying and Rusty mentioned that the Bloomberg numbers look good.  But I would actually like to see...read more
0 stars

RE:RE:RE:RE:3Q and 4Q Expectations

the 1400 patients assumption is for the US only ....add a few hundred patients in Canada and Europe and maybe Mexico.... each increment of 100 patients adds about 5 cents EPS .....So 200 patients in...read more
0 stars

RE:RE:RE:3Q and 4Q Expectations

Using the current exchange rate and the cost structure on slide 16 of the April 2015 presentation 1400 patients would translate to a cash flow per share of around 44 cents Canadian, EPS at 1400...read more
0 stars

RE:RE:3Q and 4Q Expectations

From what I understand the Canadian dollar will stay in the 75 to 80 range for at least the next 12 to 18 months. Just wondering, were the Bloomberg numbers released yesterday because of the U.S...read more
0 stars

RE:RE:3Q and 4Q Expectations

One of the best stock pickers of 2015 has a new article out bullish on TNG which had a big day on Thursday. Check it out for Friday's trading it could pop huge: http://the-gold-report.blogspot.com...read more
0 stars

RE:Sell off?

I hope not ether way. Any opinions?  rate and reply
5 stars

Sell off?

Anyone think they're maybe a pull back coming tomorrow due to sell off?  rate and reply
0 stars

RE:3Q and 4Q Expectations

The royalty payments calculations have not been disclosed but will be increasing as sales increase.....I expect TH to provide additional guidance once the royalties kick in .The favorable exchange...read more
0 stars

TH Spikes on Continued Insider Buying

http://www.cantechletter.com/2015/07/theratechnologies-spikes-as-insider-buying-continues/  rate and reply
5 stars

3Q and 4Q Expectations

By the way, the average analyst extimate for 3Q is C$0.06 and for 4Q is C$0.07. So, they expect TH to earn C$0.13 per share in the second half of 2015 but only C$0.14 in all of 2016? That is clearly...read more